Bharat Parenterals Ltd(BPLPHARMA)

NSE: BPLPHARMABSE: 541096

₹ 1,799+8.19%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 1,240 crWebsite: www.bplindia.inUpdated: 27 Oct 2026

About

Bharat Parenterals Ltd (BPL) is an Indian injectable pharmaceutical manufacturer that makes sterile formulations across general, beta-lactam and cephalosporin product lines, with two active subsidiaries: Innoxel Lifesciences, a USFDA- and EU GMP-cleared complex injectable CDMO, and Varenyam Healthcare, a domestic hospital-focused branded generics business. The group reported consolidated revenue of Rs 345.43 crores in FY26. Varenyam Healthcare is top-five in anaesthesia, pain management and critical care in India, and Innoxel holds India's only USFDA-approved oncology oral liquid manufacturing facility.^[1][2][3]

Business segments

BPL Standalone manufactures sterile injectable formulations for export and domestic institutional supply; standalone revenue was Rs 234 crores in FY26, down 23% YoY due to export tender deferrals, exit from low-margin volumes, and ~2 months of production downtime for facility upgrades.^[4]
Innoxel Lifesciences is a CDMO subsidiary developing and manufacturing complex injectables and oral liquids; revenue grew 174% YoY to Rs 72.4 crores in FY26, primarily from licensing and milestone payments.^[4]
Varenyam Healthcare is a domestic hospital-focused branded generics subsidiary; revenue grew 13.7% YoY to Rs 58.4 crores in FY26, turning PAT-profitable for the first time.^[4]

Products and portfolio

BPL is shifting product registration focus away from anti-infectives toward critical care, anaesthesia, pain, and niche CNS/CVS injectables; recent filings include Sugammadex, Tramadol, Pentazocine, Fluphenazine Decanoate, and Glyburide+Metformin.^[3]
Varenyam Healthcare markets 45 brands in anaesthesia, pain management, and critical care; it was first in India to launch Sugammadex 100mg/ml.^[2][3]
Innoxel's pipeline comprises 40+ complex injectable and oral liquid products, the majority being 505(b)(2) and ANDA candidates; 42 cumulative deals (out-licensing and CMO-CDO) were signed as of FY26.^[4][3]

Manufacturing and capacity

BPL Standalone operates three manufacturing blocks - General injectables, Beta-Lactam, and Cephalosporins - with capacity utilisation of 48%, 21%, and 24% respectively as of FY26.^[4]
Innoxel's Vadodara facility has injectable vial capacity of 6 million vials per annum, expandable to 14 million; it holds USFDA-approved status (EIR received July 2025) and EU GMP clearance from Belgian regulator FAMHP with zero critical and zero major observations.^[3][4]
BPL upgraded its general injectable vial line to ORABS standards and installed a new purified water system in the Beta-Lactam block in FY26, positioning it for PIC/S and EU GMP inspections scheduled in FY27.^[5][4]
BPL spent approximately Rs 14 crores over FY24 - FY25 to meet DCGI's revised Schedule M requirements and expand Beta-Lactam capacity.^[2]

Key operating numbers

BPL Standalone export filing base stood at 350+ live filings in 40+ countries as of FY26, supported by 214 dossier submissions and 40 new product registrations across Africa, LATAM, and Southeast Asia during FY26.^[4]
BPL Standalone order book was Rs 171 crores as of Q4 FY26.^[4]
Varenyam Healthcare productivity per medical representative (PCPM) was Rs 3.85 lakhs/month in FY26, up 31% YoY; field force stood at 211 MRs at FY26 end.^[4]
Innoxel cumulative deals reached 42 as of FY26, comprising 7 out-licensing and 35 CMO-CDO partnerships; the FY26 EBITDA loss narrowed to -Rs 6.9 crores from -Rs 30.4 crores in FY25.^[4]

Customers and distribution

Varenyam Healthcare has presence in 7,500+ hospitals across 26 states in India as of FY26, including all top corporate hospital chains.^[4][3]
Innoxel's CMO and out-licensing clients are split approximately 50% domestic MNCs and 50% international EU/US pharma companies.^[5]
BPL Standalone opened a representative office in Vietnam in FY26 to support Southeast Asia export growth.^[4]

Expansion and capex

Varenyam Biolifesciences, a new subsidiary targeting regulated emerging markets (Brazil, Colombia, South Africa, Australia), has an approved capex budget of Rs 160 crores; Rs 33 crores (CWIP) deployed as of FY26 end, with civil works 50% complete and equipment procurement ~40% done.^[4]
Varenyam Biolifesciences commissioning is targeted for September 2027, line validation by March 2028, first EU GMP regulatory filing in Q1 FY29, and first commercial supply in Q4 FY29.^[4]

Recent developments

Innoxel received the USFDA Establishment Inspection Report on 30 July 2025, confirming USFDA-approved status for its Vadodara facility after completing its inspection in April - May 2025 with one minor observation.^[5][2]
Innoxel was cleared by FAMHP (Belgian regulator) for EU GMP with zero critical and zero major observations in FY26, opening the path to commercial supply to the EU and selected European markets.^[4]
Innoxel posted EBITDA of Rs 1.4 crores in Q4 FY26, its first EBITDA-positive quarter since inception.^[4]
Varenyam Healthcare swung to PAT profit of Rs 2.3 crores in FY26 from a PAT loss of Rs 2.1 crores in FY25, the first year of profitability.^[4]
Innoxel signed 23 new deals in FY26 (7 out-licensing, 16 CMO-CDO), bringing cumulative deals to 42; first commercial CMO supply is targeted for Q2 FY27.^[4]

Market Cap

₹1,240 Cr

High / Low

₹2,274 / 880

Stock P/E

-74.0

Price / Book

3.5

Book Value

₹468

EPS

₹-11.9

No. of Shares

0.69 Cr

ROCE

-1.8%

ROE

-2.5%

OPM

-2.5%

Debt / Equity

0.45

Sales

₹345 Cr

Net Profit

₹-27 Cr

Promoter holding

67.2%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials